ArticleNature immunology2025
Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression.
Abstract read
In one paragraph
Article in Nature immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- DRP1 depletion protects NK cells from hypoxia-induced dysfunction.Redox report : communications in free radical research · 2026Article
- PTPN22 as a novel therapeutic target: a key intracellular checkpoint for NK cell therapy.Journal for immunotherapy of cancer · 2026Article
- Plasma membrane order maps functional diversity in immune cells.Nature chemical biology · 2026Article
- Tissue-Resident Macrophage in Inflammation and Cancer.MedComm · 2026Review
- Natural Killer Cell Immunotherapy in Solid Tumors: Microenvironmental Obstacles and Translational 3D Models.Biology · 2026Review
- Next-generation CAR-NK cell therapy: engineering strategies, translational challenges, and future perspectives in cancer immunotherapy.Cancer cell international · 2026Review
- SMAD7 drives natural killer cell antitumor activity through canonical TGF-β blockade and non-canonical transcriptional activation of STAT5A.Journal for immunotherapy of cancer · 2026Article
- Review
- The TGF-βR1 inhibitor galunisertib re-shapes the PDAC-TME by limiting decidual-like natural killer cells polarization.Cell death & disease · 2026Article
- Lactate-mediated NK cell dysfunction as a prognostic marker and therapeutic target in breast cancer.Cell death discovery · 2026Article
- CAR-NK cell therapy for hematologic malignancies: advances, challenges and optimization strategies.Molecular cancer · 2026Review
- Artificial intelligence-assisted spatial omics-based biomimetic nanoplatform for intelligent and precise intervention in the immunosuppressive core region of ovarian cancer.NPJ precision oncology · 2026Review
- Transcriptional networks weaving natural killer anti-tumor immune response.Molecular cancer · 2026Review
- Phenotypically similar but functionally distinct NK cell populations within the human maternal-fetal interface.ImmunoHorizons · 2026Article
- Engineering Bi-Specific CAR-NK Cells to Restore Antibody-Dependent Cellular Cytotoxicity in Solid Tumors.Cells · 2026Article
- Current development and challenges of NK cell-based immunotherapy for gastrointestinal cancers.International journal of clinical oncology · 2026Review
- Dual Regulation of Post-Translational Modification of Proteins: Bottlenecks and Breakthroughs in NK Cell Therapy for Glioblastoma.International journal of general medicine · 2026Review
- Natural Killer Cell Therapy in Ovarian Cancer: From Preclinical Potentials to Clinical Applications and Combination Strategies.International journal of biological sciences · 2026Review
- One-step knock-in CAR constructs in human NK cells enable scalable, TGFβ1-resistant immunotherapy for solid tumors.Theranostics · 2026Article
- Targeting innate immunity in cancer: mechanistic foundations, therapeutic vaccination, and clinical translation.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Anna ReaUniversity Pompeu Fabra (UPF), Barcelona, Spain.
Sara Santana-HernándezHospital del Mar Research Institute (IMIM), Barcelona, Spain.ORCID http://orcid.org/0000-0001-7440-8445
Javier VillanuevaUniversity Pompeu Fabra (UPF), Barcelona, Spain.
Marta Sanvicente-GarcíaUniversity Pompeu Fabra (UPF), Barcelona, Spain.ORCID http://orcid.org/0000-0002-4508-2834
Mariona CaboHospital del Mar Research Institute (IMIM), Barcelona, Spain.
Jesús Suarez-OlmosHospital del Mar Research Institute (IMIM), Barcelona, Spain.
Fabricio QuimisHospital del Mar Research Institute (IMIM), Barcelona, Spain.
Mengjuan QinHospital del Mar Research Institute (IMIM), Barcelona, Spain.ORCID http://orcid.org/0000-0001-7014-7188
Eduard LlorensHospital del Mar Research Institute (IMIM), Barcelona, Spain.
Sandra Blasco-BenitoHospital del Mar Research Institute (IMIM), Barcelona, Spain.
Lamberto Torralba-RagaPrecision Immunotherapy Alliance, The University of Oslo, Oslo, Norway.
Lorena PerezDepartment of Immunology, Hospital Clínic de Barcelona (HCB), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Joint Platform of Immunotherapy Hospital Sant Joan de Deu - HCB, University of Barcelona, Barcelona, Spain.
Bishan BhattaraiDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Elisenda Alari-PahissaHospital del Mar Research Institute (IMIM), Barcelona, Spain.ORCID http://orcid.org/0000-0001-7424-5383
Anna-Maria GeorgoudakiGlycostem Therapeutics, Oss, the Netherlands.
Francesc BalaguerDepartment of Gastroenterology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Spain.
Manel JuanDepartment of Immunology, Hospital Clínic de Barcelona (HCB), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Joint Platform of Immunotherapy Hospital Sant Joan de Deu - HCB, University of Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0002-3064-1648
Julián PardoIIS Aragon Foundation/ Dpt. Microbiology, Radiology Pediatry and Public Health, University of Zaragoza, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERinfec), Zaragoza, Spain.ORCID http://orcid.org/0000-0003-0154-0730
Toni Celià-TerrassaHospital del Mar Research Institute (IMIM), Barcelona, Spain.
Ana RoviraHospital del Mar Research Institute (IMIM), Barcelona, Spain.ORCID http://orcid.org/0000-0003-1301-2599
Nina MökerMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Congcong ZhangMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Marco ColonnaDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0001-5222-4987
Jan SpanholtzGlycostem Therapeutics, Oss, the Netherlands.ORCID http://orcid.org/0000-0001-7152-6956
Karl-Johan MalmbergPrecision Immunotherapy Alliance, The University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0002-8718-9373
Clara MontagutUniversity Pompeu Fabra (UPF), Barcelona, Spain.
Joan AlbanellUniversity Pompeu Fabra (UPF), Barcelona, Spain.
Marc GüellUniversity Pompeu Fabra (UPF), Barcelona, Spain.ORCID http://orcid.org/0000-0003-4000-7912
Miguel López-BotetUniversity Pompeu Fabra (UPF), Barcelona, Spain.ORCID http://orcid.org/0000-0003-4882-065X
Aura MuntasellHospital del Mar Research Institute (IMIM), Barcelona, Spain. aura.muntasell@uab.cat.ORCID http://orcid.org/0000-0003-2894-0486
Funding
Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2MDepartament d'Innovació, Universitats i Empresa, Generalitat de Catalunya (Department of Innovation, Education and Enterprise, Government of Catalonia) 2024PROD00089EC | EC Seventh Framework Programm | FP7 People: Marie-Curie Actions (FP7-PEOPLE - Specific Programme "People" Implementing the Seventh Framework Programme of the European Community for Research, Technological Development and Demonstration Activities (2007 to 2013)) 765104EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 Marie Sklodowska-Curie Actions (H2020 Excellent Science - Marie Sklodowska-Curie Actions) 765104Generalitat de Catalunya (Government of Catalonia) SGR863Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) FI23/00075Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) ICI24/00041Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI21/00002Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI22/00040NCI NIH HHS P01 CA111412
Abstract
Transforming growth factor beta (TGFβ) and activin A suppress natural killer (NK) cell function and proliferation, limiting the efficacy of adoptive NK cell therapies. Inspired by the partial resistance to TGFβ of NK cells with SMAD4 haploinsufficiency, we used CRISPR-Cas9 for knockout of SMAD4 in human NK cells. Here we show that SMAD4
Indexed as
ActivinsKiller Cells, NaturalNeoplasmsSmad4 ProteinTransforming Growth Factor betaAnimalsCell Line, TumorCRISPR-Cas SystemsCytotoxicity, ImmunologicGene Knockout TechniquesHumansImmunotherapy, AdoptiveMiceSignal Transductionactivin AActivinsSmad4 ProteinSMAD4 protein, humanTransforming Growth Factor beta
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.